Bethlehem, PA, March 12, 2012 – Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today it has entered into a distribution agreement with INyDIA Labs, based in Madrid, Spain, for My5-FU™, a test that measures levels of a widely-used anti-cancer drug, 5-fluorouracil (5-FU), in the blood of cancer patients.
http://www.lsgpa.com/saladax-biomedical-expands-distribution-my5-fu-spain-portugal/937/
Committed to advancing the life sciences and improving the lives of Pennsylvanians through innovations in healthcare and enhanced economic opportunity. Since 2002, we have been actively funding healthcare technology companies in their very earliest stages, from emerging entities and companies seeking to expand or relocate, to university-based researchers or technology development groups. www.lsgpa.com
Monday, March 12, 2012
Monday, March 5, 2012
Penn State College of Medicine
Penn State College of Medicine
announced this morning it has been awarded a $425,000 grant as part of
the Discovered in PA, Developed in PA program, from the Pennsylvania
Department of Community and Economic Development.
Read the full article here: http://www.pennlive.com/midstate/index.ssf/2012/03/penn_state_college_of_medicine_7.html
Read the full article here: http://www.pennlive.com/midstate/index.ssf/2012/03/penn_state_college_of_medicine_7.html
Thursday, March 1, 2012
The Life Sciences Greenhouse's Newest Investment
LSGPA INVESTS $250,000 IN MICRO INTERVENTIONAL DEVICES, INC.
Medical Device Developer Striving to
Make Cardiac Surgery
Faster, Safer and Less Costly
Bethlehem, PA – March
1, 2012. The Life Sciences
Greenhouse of Central Pennsylvania (LSGPA) announced today an investment of $250,000
in Micro Interventional Devices, Inc. (MID), a developer of structural heart
repair technologies.
MID’s initial product offering is a minimally invasive
device known as Permaseal™, which provides access and wound closure during
structural heart repair procedures. Designed
to move with the beating heart while still keeping the edges of the wound
closed, the Permaseal device not only enables wound healing without the use of
sutures, it is cost- and time-efficient.
“The Permaseal access and closure device will enable
unprecedented safe and reliable transmyocardial access for structural heart
repair procedures,” says Michael Whitman, President & CEO. “It is our hope that Permaseal becomes the
new standard of care for access and closure for these procedures.”
The patent pending Permaseal technology allows the surgeon
to remotely affix a biocompatible implant to the apex of the heart, creating an
“access site” on the myocardial surface of the heart. This provides sutureless
access for a wide range of structural heart repair procedures including transcatheter
aortic valve implantation (TAVI), transcatheter mitral valve replacement,
mitral valve repair and other emerging structural heart repair procedures.
Subscribe to:
Posts (Atom)